Population
Patients presenting with acute coronary syndromes requiring antithrombotic therapy and revascularization.
Design
Review
Authors
Loading...
Supports bleeding risk assessment in ACS; leaves open whether CRUSADE-guided therapy improves outcomes in randomized trials.
Careful assessment of bleeding risk factors using standardized scores allows for the customization of antithrombotic therapy in ACS patients to minimize mortality from both ischemic and hemorrhagic events.
Buergler et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: